Thomas Kowalski Email Address

Chair

Duane Morris LLP, a law firm with more than 750 attorneys in offices across the United States and internationally, is asked by a broad array of clients to provide innovative solutions to today's legal and business challenges. From a partnership of four Philadelphia attorneys in 1904, the firm has grown to be among the 100 largest in the world. Duane Morris'a lawyers now work out of offices in North America, Europe and Asia to address clients'a issues around the globe. See the Harvard Business Schoolas second case study of the firm titled aCollaborating for Growth: Duane Morris in a Turbulent Legal Sector.a Throughout all the growth, Duane Morris always has been guided by the same principle. At the heart of the firm is a partnership, an agreement to work together in the pursuit of its clients'a goals. Under the leadership of the firm's founders, and the influence of past and present chairmen, Duane Morris has embraced a culture of inclusiveness, congeniality and consensus building that is rare among law firms.

*Select inter partes / advocacy matters - Merial, Inc. v Intervet International B.V. (No 3) [2017] FCA 21 (25 January 2017) (http://www6.austlii.edu.au/cgi-bin/viewdoc/au/cases/cth/federal_ct/2017/21.html) Testifying: 6 Sept 12 USPTO FITF; 16 Feb 12 USPTO Genetic Diagnostic Testing; 25 Oct 11 USPTO Prior User Rights (Report to Congress) Ass'n for Molecular Pathology v Myriad Genetics, Inc, No. 12-398 (US Sup Ct) (NYIPLA Brief) FTC v Activis, Inc, No 12-416 (US Sup Ct) (NYIPLA Brief; Counsel of Record) Bowman v Monsanto Co, No 11-796 (US Sup Ct) (NYIPLA Brief) Merck & Co., Inc. v Louisiana Wholesale Drug Co, Inc, Nos 12-245 & 12-265 (US Sup Ct) (NYIPLA Brief) Ass'n for Molecular Pathology v Myriad Genetics, Inc, No. 2010-1406 (Fed Cir) (PSC Brief) Intervet Inc v Merial Ltd, 617 F3d 1282 (Fed Cir 2010), rev'ing 643 FSupp2d 97 (DDC 2009) & 2007 WL 5685349 (DDC Nov 28, 2007); Intervet, Inc v Merial Ltd, 241 FRD 55 (DDC 2007); Intervet, Inc v Merial Ltd, 2008 WL 18357257, DNeb. (Apr 22, 2008); Intervet, Inc v Merial Ltd, 256 FRD 229 (DDC 2009); Intervet, Inc v Merial Ltd, 655 FSupp2d 131 (DDC 2009) In re PCV Vaccine Products Patent Litigation, MDL No 2095 (2009) Bavarian Nordic A/S v Oxford BioMedica PLC, No 08cv1156 (SDCa) Gray v Kingsman, Interference No 105,672 Dawson v Dallavalle, 85 USPQ2d 540 (BPAI 2007) Danisco A/S et al v Novozymes A/S et al, 427 FSupp 443 (SDNY 2006) *Selection of US patents - 8,697,359; 8,771,945; 8,795,965; 8,865,406; 8,871,445; 8,889,356; 8,895,308; 8,906,616; 8,932,814; 8,945,839; 8,993,233; 8,999,641 (CRISPR Patents of Interference 106,048) 7,860,658 7,807,398 7,790,962 7,790,419 7,678,544 7,767,449 (Modified vaccinia) 7,740,863 7,718,356 7,700,625 7,678,544 7,659,299 7,658,341 7,655,776 7,622,555 7,582,302 7,449,495 7,498,038 7,390,795 7,250,161 7,220,412 (Undifferentiated cell) 7,122,532 6,852,346 (Lipase) 6,368,601 (PCV2) 5,688,512 (Substantially pure OspA) 5,505,941 (Recombinant avipox) D607,999